Product Code: MD 5119
"The topical drug delivery market is projected to grow at a CAGR of 5.7% during the forecast period (2019-2024)."
The topical drug delivery market is projected to reach USD 123.2 billion by 2024 from USD 93.2 billion in 2019, at a CAGR of 5.7%. The growth of the topical drug delivery market is driven mainly by the high prevalence of skin disease, rising incidences of eye diseases, high incidence of burn injuries, and the growing prevalence of diabetes. Additionally, emerging markets such as China and India are expected to offer potential growth opportunities to market players in the coming years. However, preference for alternative modes of drug delivery such as oral, injectables, pulmonary, among others could restrict the growth of this market.
By product, the semi-solid formulations segment is expected to account for the largest share of the topical drug delivery market
Based on product, the topical drug delivery market is segmented into semi-solid formulations (creams, gels, ointments, pastes, and lotions), solid formulations (suppositories and powders), liquid formulations (solutions and suspensions), and transdermal products (transdermal patches and transdermal semi-solids). The semi-solid formulations segment is expected to account the largest market share of the topical drug delivery market in 2019. This is mainly due to their easy application and ability to topically deliver a wide variety of drug molecules compared to other formulations.
By route of administration, dermal drug delivery segment to dominate the topical drug delivery market during the forecast period
The dermal drug delivery segment accounted for the largest share of the market in 2018. This is mainly due to the high prevalence of skin diseases across the globe. For instance, According to the WHO, between 2 and 3 million cases of non-melanoma skin cancer and 132,000 cases of melanoma skin cancer are diagnosed annually across the globe.
By facility of use, homecare settings segment to dominate the topical drug delivery market during the forecast period
The homecare settings segment accounted for the largest share of the market in 2018. This is mainly due to the ease of use of topical products at home, better affordability, and advantages of topical and transdermal patches for patients who require a constant drug level as well as those suffering from chronic diseases at homecare settings.
"North America is expected to witness the highest growth during the forecast period."
North America is expected to account for the largest share of the global topical drug delivery market in 2019, followed by Europe. However, Japan is expected to witness the highest CAGR during the forecast period. This can primarily be attributed to the rising geriatric population, increasing the inflow of generic drugs, a growing number of product approvals and launches, and the increasing focus of local players on the R&D of topical formulations in the country. For instance, in November 2018, Santen Pharmaceutical Co., Ltd. (Japan) and Ube Industries (Japan) launched the topical EYBELIS Ophthalmic Solution 0.002% in Japan. Similarly, in September 2018, Santen Pharmaceutical Co., Ltd. (Japan) signed a development and drug discovery agreement with PeptiDerm Inc. (Japan) for developing topical ophthalmic products. Furthermore, in June 2017, LEO Pharma (Denmark) partnered with Kyowa Hakko Kirin Co., Ltd. (Japan) for the development of a topical gel formulation for the treatment of psoriasis.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1-55%, Tier 2-25%, and Tier 3-20%
- By Designation: C-level-43%, Director-level-32%, and Others-25%
- By Region: North America-38%, Europe-29%, Asia Pacific-23%, Rest of World-10%
The prominent players in the topical drug delivery market are: Nestle SA (Switzerland), Johnson & Johnson (US), Bausch Health Companies (Canada), Novartis AG (Switzerland), GlaxoSmithKline (UK), Bayer AG (Germany), Hisamitsu Pharmaceutical (Japan), Mylan (US) Glenmark Pharmaceuticals (India), Cipla Ltd (India), Crescita Therapeutics Inc. (Canada), and Merck & Co (US).
Research Coverage:
The report analyzes the topical drug delivery market and aims at estimating the market size and future growth potential of the topical drug delivery market and the different segments such as dermal, ophthalmic, rectal, vaginal, and nasal drug delivery. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.
Reasons to Buy the Report:
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies for strengthening their market presence.
This report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the topical drug delivery market.
- Product & Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launch in the topical drug delivery market.
- Market Development: Comprehensive information on lucrative emerging regions.
- Market Diversification: Exhaustive information about new products and services, growing geographies, and recent developments in the global topical drug delivery market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products & services of the leading players in the topical drug delivery market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
- 1.3.1 MARKETS COVERED
- 1.3.2 YEARS CONSIDERED FOR THE STUDY
- 1.4 CURRENCY
- 1.5 LIMITATIONS
- 1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.1.1 Key data from secondary sources
- 2.1.2 PRIMARY DATA
- 2.1.2.1 Key data from primary sources
- 2.1.2.2 Key industry insights
- 2.2 MARKET SIZE ESTIMATION
- 2.2.1 BOTTOM-UP APPROACH
- 2.2.2 TOP-DOWN APPROACH
- 2.2.3 GROWTH FORECAST
- 2.3 MARKET DATA VALIDATION AND TRIANGULATION
- 2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 TOPICAL DRUG DELIVERY MARKET OVERVIEW
- 4.2 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2018
- 4.3 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2018
- 4.4 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 High prevalence of skin diseases
- 5.2.1.2 Rising prevalence of eye diseases
- 5.2.1.3 High incidence of burn injuries
- 5.2.1.4 Growing prevalence of diabetes
- 5.2.2 RESTRAINTS
- 5.2.2.1 Preference for alternative modes of drug delivery
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Delivery of biologics through the transdermal route
- 5.2.3.2 Self-administration and home care
- 5.2.4 CHALLENGES
- 5.2.4.1 Technical barriers related to skin irritation and permeability
- 5.2.4.2 Drug failures and product recalls
6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT
- 6.1 INTRODUCTION
- 6.2 SEMI-SOLID FORMULATIONS
- 6.2.1 CREAMS
- 6.2.1.1 Ease of spreadability and washability to drive this market segment
- 6.2.2 OINTMENTS
- 6.2.2.1 Ointments are widely used in analgesic indications
- 6.2.3 LOTIONS
- 6.2.3.1 Easy administration of lotions to drive their demand among end users
- 6.2.4 GELS
- 6.2.4.1 Faster drug release and greater patient acceptability to drive the market for topical gels
- 6.2.5 PASTES
- 6.2.5.1 Topical pastes are widely used for the treatment and prevention of skin irritation
- 6.3 LIQUID FORMULATIONS
- 6.3.1 SUSPENSIONS
- 6.3.1.1 Higher rate of bioavailability and controlled onset of action to support the growth of the topical suspensions market
- 6.3.2 SOLUTIONS
- 6.3.2.1 Topical solutions comprise soluble chemicals that are dissolved in various solvents
- 6.4 SOLID FORMULATIONS
- 6.4.1 POWDERS
- 6.4.1.1 Powders have a very fine particle size that covers a large surface area per unit weight
- 6.4.2 SUPPOSITORIES
- 6.4.2.1 Suppositories require a suitable base that ensures the compatibility and stability of the drug
- 6.5 TRANSDERMAL PRODUCTS
- 6.5.1 TRANSDERMAL PATCHES
- 6.5.1.1 Transdermal patches to account for the largest share of
the transdermal drug delivery market in 2019 60
- 6.5.2 TRANSDERMAL SEMI-SOLIDS
- 6.5.2.1 Transdermal semi-solids segment to witness negative growth during the forecast period
7 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION
- 7.1 INTRODUCTION
- 7.2 DERMAL DRUG DELIVERY
- 7.2.1 DERMAL DRUG DELIVERY IS THE LARGEST SEGMENT IN THIS MARKET DUE TO ADVANTAGES SUCH AS EASE OF USE AND INCREASED PATIENT COMPLIANCE
- 7.3 OPHTHALMIC DRUG DELIVERY
- 7.3.1 INCREASING USE OF MOBILE DEVICES IS LIKELY TO IMPACT VISION, WHICH IS A KEY FACTOR SUPPORTING MARKET GROWTH
- 7.4 RECTAL DRUG DELIVERY
- 7.4.1 POOR ABSORPTION OF DRUGS THROUGH THE RECTAL ROUTE-A KEY DISADVANTAGE ASSOCIATED WITH THIS MARKET SEGMENT
- 7.5 VAGINAL DRUG DELIVERY
- 7.5.1 HIGH PERMEABILITY OF VAGINAL TISSUES, THE SCOPE OF SELF-ADMINISTRATION, AND EASE OF MANUFACTURING ARE EXPECTED TO BOOST THE GROWTH OF THE VAGINAL DRUG DELIVERY MARKET SEGMENT
- 7.6 NASAL DRUG DELIVERY
- 7.6.1 ABSENCE OF DRUG DEGRADATION, HIGH EFFICACY OF NASALLY ADMINISTERED DRUGS, AND GROWING PREFERENCE FOR SELF-ADMINISTRATION TO DRIVE MARKET GROWTH
8 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE
- 8.1 INTRODUCTION
- 8.2 HOME CARE SETTINGS
- 8.2.1 HOME CARE SETTINGS ACCOUNTED FOR THE LARGEST SHARE IN 2018
- 8.3 HOSPITALS AND CLINICS
- 8.3.1 RISING INCIDENCE OF SURGICAL SITE INFECTIONS TO DRIVE THIS SEGMENT
- 8.4 BURN CENTERS
- 8.4.1 HIGH INCIDENCE OF BURN INJURIES ACROSS THE GLOBE TO SUPPORT
THE MARKET GROWTH 76
9 TOPICAL DRUG DELIVERY MARKET, BY REGION
- 9.1 INTRODUCTION
- 9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.1.1 Rising prevalence of skin diseases and the approval and launch of innovative topical formulations-key factors driving market growth
- 9.2.2 CANADA
- 9.2.2.1 Rising prevalence of skin diseases and funding for the development of topical drugs to drive market growth
- 9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.1.1 Growing focus of pharmaceutical companies on the development of topical products to drive market growth
- 9.3.2 UK
- 9.3.2.1 Rising prevalence of skin diseases & chronic conditions to drive market growth
- 9.3.3 FRANCE
- 9.3.3.1 Rising prevalence of skin diseases and development of topical drugs by local players to support market growth
- 9.3.4 REST OF EUROPE
- 9.4 ASIA PACIFIC
- 9.4.1 JAPAN
- 9.4.1.1 Increasing number of product approvals and growing focus of local players on the R&D of topical formulations to support market growth
- 9.4.2 CHINA
- 9.4.2.1 Growing focus of major players in China on the development of topical drugs to drive market growth
- 9.4.3 INDIA
- 9.4.3.1 Rising awareness among healthcare providers & patients and increasing focus on noninvasive methods of drug delivery
to drive market growth 132
- 9.4.4 REST OF ASIA PACIFIC
- 9.5 REST OF THE WORLD
10 COMPETITIVE LANDSCAPE
- 10.1 OVERVIEW
- 10.2 MARKET SHARE ANALYSIS
- 10.2.1 JOHNSON & JOHNSON
- 10.2.2 NESTLE SA (GALDERMA)
- 10.2.3 NOVARTIS
- 10.3 COMPETITIVE SCENARIO
- 10.3.1 PRODUCT LAUNCHES
- 10.3.2 EXPANSIONS
- 10.3.3 AGREEMENTS AND COLLABORATIONS
- 10.3.4 ACQUISITIONS
- 10.4 COMPETITIVE LEADERSHIP MAPPING (OVERALL MARKET) (2018)
- 10.4.1 VISIONARY LEADERS
- 10.4.2 INNOVATORS
- 10.4.3 DYNAMIC DIFFERENTIATORS
- 10.4.4 EMERGING COMPANIES
11 COMPANY PROFILES
(Business overview, Products offered, Recent developments, MNM view)*
- 11.1 GLAXOSMITHKLINE
- 11.2 JANSSEN GLOBAL SERVICES (A SUBSIDIARY OF JOHNSON & JOHNSON)
- 11.3 BAUSCH HEALTH COMPANIES
- 11.4 MERCK & CO.
- 11.5 BAYER AG
- 11.6 HISAMITSU PHARMACEUTICAL
- 11.7 NESTLE SA
- 11.8 NOVARTIS AG
- 11.9 GLENMARK PHARMACEUTICALS
- 11.10 CIPLA
- 11.11 CRESCITA THERAPEUTICS INC.
- 11.12 MYLAN N.V.
Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.
12 APPENDIX
- 12.1 DISCUSSION GUIDE
- 12.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 12.3 RELATED REPORTS
- 12.4 AUTHOR DETAILS
